Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages vi64-vi68

  Fizazi, K ^a   Greco, F A ^b   Pavlidis, N ^c   Daugaard, G ^d   Oien, K ^e   Pentheroudakis, G ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTENNIAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; FOLLOW UP; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPHOMA; MEDICAL SOCIETY; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMOR; ONCOLOGY; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SARCOMA; THYROID CANCER; UNDIFFERENTIATED CARCINOMA; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY;

HUMANS; NEOPLASMS, UNKNOWN PRIMARY;

EID: 84941644054     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv305     Document Type: Article

References (32)

1. Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol 2011; 8: 701-710.
2. Vikeså J, Møller AK, Kaczkowski B et al. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. BMC Cancer 2015; 15: 151.
3. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36: 8-37.
4. Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
5. Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res 2007; 1: 229-235.
6. Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013; 105: 782-790.
7. Hainsworth JD, Rubin MS, Spigel DR et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research institute. J Clin Oncol 2013; 31: 217-223.
8. Pillai R, Deeter R, Rigl CT et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 2011; 13: 48-56.
9. Kerr SE, Schnabel CA, Sullivan PS et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012; 18: 3952-3960.
10. Meiri E, Mueller WC, Rosenwald S et al. A second-generation microRNAbased assay for diagnosing tumor tissue origin. Oncologist 2012; 17: 801-812.
11. Pentheroudakis G, Spector Y, Krikelis D et al. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastasis 2013; 30: 431-439.
12. Gross-Goupil M, Massard C, Lesimple T et al. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie 2012; 35: 54-55.
13. Hainsworth JD, Greco FA. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch 2014; 464: 393-402.
14. Moller AK, Loft A, Berthelsen AK et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012; 17: 1146-1154.
15. Seve P, Billotey C, Broussolle C et al. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-299.
16. Hainsworth JD, Schnabel CA, Erlander MG et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012; 11: 112-118.
17. Culine S, Kramar A, Saghatchian M et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 4679-4683.
18. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36: 52-59.
19. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 2010; 75: 27-42.
20. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 2010; 119: 1-11.
21. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009; 11: 340-348.
22. Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 2009; 36: 44-51.
23. Bugat R, Bataillard A, Lesimple T et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89(Suppl 1): S59-S66.
24. Golfinopoulos V, Pentheroudakis G, Salanti G et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multipletreatments meta-analysis. Cancer Treat Rev 2009; 35: 570-573.
25. Hainsworth JD, Spigel DR, Clark BL et al. Paclitaxel/carboplatin/etopside versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomised phase III Sarah Cannon Research Consortium Trial. Cancer J 2010; 16: 70-75.
26. Culine S, Lortholary A, Voigt JJ et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study-Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21: 3479-3482.
27. Gross-Goupil M, Fourcade A, Blot E et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomized GEFCAPI 02 trial. Eur J Cancer 2012; 48: 721-727.
28. Levy A, Massard C, Gross-Goupil M, Fizazi K. Carcinomas of an unknown primary site: a curable disease? Ann Oncol 2008; 19: 1657-1658.
29. Massard C, Voigt JJ, Laplanche A et al. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 2007; 97: 857-861.
30. Hainsworth JD, Daugaard G, Lesimple T et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial. Cancer 2015; 121: 1654-1661.
31. Varadhachary GR, Raber MN, Matamorous A, Abbruzzese JL. Carcinoma of unknown primary with colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008; 9: 596-599.
32. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.